SCHEMBL1672832

SCHEMBL1672832

COCc1nn2c(C(F)(F)F)cnc2s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 3/20 0.34
TSHR P16473 3/20 0.34
ALDH1A1 P00352 2/20 0.34
BCHE P06276 4/20 0.33
HTT P42858 2/20 0.33
HPGD P15428 2/20 0.33
USP2 O75604 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HIF1A Q16665 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PIK3CA P42336 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1671683 0.86 POLB (0.35) MAPTPOLBPIK3CA
SCHEMBL1671681 0.77 MAPT (0.39) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL1672158 0.77 MEN1 (0.38) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL23415150 0.70 ALPL (0.58)
SCHEMBL23415199 0.69 MEN1 (0.34) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL13723919 0.69 TP53 (0.35) MAPTTP53SMN1; SMN2
SCHEMBL13724043 0.68 TP53 (0.34) MAPTTP53SMN1; SMN2POLB
SCHEMBL13723917 0.68 TP53 (0.34) MAPTTP53SMN1; SMN2
SCHEMBL1672831 0.68 TP53 (0.54) MAPTTP53SMN1; SMN2
SCHEMBL21138063 0.64 TP53 (0.65) MAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790885-B1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB Biopharma SRL (BE) 2023-04-19 EP disclosed
US-11286266-B2 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives UCB Biopharma SRL 2022-03-29 US disclosed
US-11155565-B2 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives UCB Biopharma SRL 2021-10-26 US disclosed
EP-3652183-B1 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Biopharma SRL (BE) 2021-09-08 EP disclosed
US-20210107922-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2021-04-15 US disclosed
EP-3790885-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB Biopharma SRL (BE) 2021-03-17 EP disclosed
US-20200231599-A1 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2020-07-23 US disclosed
WO-2019215062-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-11-14 WO disclosed
WO-2019215062-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-11-14 WO disclosed
WO-2019011770-A1 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-01-17 WO disclosed
EP-2491045-B1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2015-12-23 EP disclosed
US-8822508-B2 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives UCB PHARMA, S.A. (BE) 2014-09-02 US disclosed
US-20120245208-A1 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives UCB PHARMA, S.A. (BE) 2012-09-27 US disclosed
EP-2491045-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Pharma S.A. (BE) 2012-08-29 EP disclosed
WO-2011047860-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB PHARMA, S.A. (BE) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155565-B2 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives CYP3A43, CYP3A4, CYP3A7 MAPT 2052/4885TP53 3658/4885SMN1; SMN2 2340/4885
US-11286266-B2 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives TPMT, THPO, PKD1 MAPT 570/4885TP53 2196/4885SMN1; SMN2 2243/4885
US-20200231599-A1 2-OXO-1,3-OXAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES CYP3A43, CYP3A4, CYP3A7 MAPT 2052/4885TP53 3658/4885SMN1; SMN2 2340/4885
US-20210107922-A1 1-IMIDAZOTHIADIAZOLO-2H-PYRROL-5-ONE DERIVATIVES TPMT, THPO, PKD1 MAPT 570/4885TP53 2196/4885SMN1; SMN2 2243/4885
US-20120245208-A1 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives CYP3A4, CYP3A43, CYP3A7 MAPT 1016/4885TP53 2687/4885SMN1; SMN2 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.